{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:12:58Z","timestamp":1771045978929,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jcf.2022.06.004","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T21:49:35Z","timestamp":1655934575000},"page":"1070-1073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Eruptive melanocytic naevi following initiation of elexacaftor\/ivacaftor\/tezacaftor for cystic fibrosis"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3378-828X","authenticated-orcid":false,"given":"Michael","family":"Atkinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3161-1053","authenticated-orcid":false,"given":"Oliver","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niall","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Walshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9334-486X","authenticated-orcid":false,"given":"Thomas Simon","family":"FitzMaurice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jcf.2022.06.004_bib0001","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nm.2715","article-title":"Cystic fibrosis: a mucosal immunodeficiency syndrome","volume":"18","author":"Cohen","year":"2012","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jcf.2022.06.004_bib0002","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2016.04.064","article-title":"Eruptive nevi associated with medications (enams)","volume":"75","author":"Perry","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jcf.2022.06.004_bib0003","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s40257-019-00444-8","article-title":"Eruptive melanocytic Nevi: a Review","volume":"20","author":"Burian","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jcf.2022.06.004_bib0004","article-title":"A phase 3 study of VX-445 combination therapy in subjects with cystic fibrosis heterozygous for the F508del mutation and a minimal function mutation (F\/MF) \u2013 study results [Internet]","year":"2020","journal-title":"Study Results \u2013 Clin Trials.gov"},{"key":"10.1016\/j.jcf.2022.06.004_bib0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdcr.2021.10.018","article-title":"Urticaria multiforme-like eruption due to a novel agent elexacaftor\/tezacaftor\/ivacaftor in a pediatric patient with cystic fibrosis","volume":"18","author":"Goldberg","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jcf.2022.06.004_bib0006","first-page":"15","article-title":"Elexacaftor, tezacaftor and ivacaftor: a case of severe rash and approach to desensitisation","author":"Cheng","year":"2022","journal-title":"BMJ Case Rep"},{"issue":"8","key":"10.1016\/j.jcf.2022.06.004_bib0007","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/ppul.25437","article-title":"CFTR modulator drug desensitization: preserving the hope of long term improvement","volume":"56","author":"Leonhardt","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"11","key":"10.1016\/j.jcf.2022.06.004_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/jid.2012.175","article-title":"PDZK1 upregulation in estrogen-related hyperpigmentation in Melasma","volume":"132","author":"Kim","year":"2012","journal-title":"J Investigat Dermatol"},{"key":"10.1016\/j.jcf.2022.06.004_bib0009","series-title":"Trikafta [package insert]","year":"2019"},{"issue":"6","key":"10.1016\/j.jcf.2022.06.004_bib0010","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0190-9622(03)02482-4","article-title":"Eruptive melanocytic nevi in patients with renal allografts: report of 10 cases with dermoscopic findings","volume":"49","author":"Alaibac","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jcf.2022.06.004_bib0011","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1684\/ejd.2014.2462","article-title":"Eruptive nevi and hair depigmentation related to regorafenib","volume":"25","author":"Sibaud","year":"2015","journal-title":"Europ J Dermatol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322005902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322005902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:48:10Z","timestamp":1761601690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199322005902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1569199322005902"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2022.06.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eruptive melanocytic naevi following initiation of elexacaftor\/ivacaftor\/tezacaftor for cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2022.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}